Deutsche Bank
RLMD icon

Deutsche Bank’s Relmada Therapeutics RLMD Stock Holding History

Deutsche Bank’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
318,902
+94,056
+42% +$657K ﹤0.01% 1851
2026
Q1 		$1.56M Hold
224,846
– – ﹤0.01% 1919
2025
Q4 		$1.09M Hold
224,846
– – ﹤0.01% 2153
2025
Q3 		$452K Hold
224,846
– – ﹤0.01% 2599
2025
Q2 		$135K Hold
224,846
– – ﹤0.01% 3141
2025
Q1 		$60.7K Hold
224,846
– – ﹤0.01% 3340
2024
Q4 		$117K Hold
224,846
– – ﹤0.01% 3250
2024
Q3 		$729K Hold
224,846
– – ﹤0.01% 2270
2024
Q2 		$675K Hold
224,846
– – ﹤0.01% 2188
2024
Q1 		$1.05M Hold
224,846
– – ﹤0.01% 1999
2023
Q4 		$931K Buy
224,846
+219,887
+4,434% +$651K ﹤0.01% 2068
2023
Q3 		$14.9K Sell
4,959
-233,338
-98% -$693K ﹤0.01% 3529
2023
Q2 		$586K Sell
238,297
-16,445
-6% -$45.5K ﹤0.01% 2271
2023
Q1 		$576K Buy
254,742
+15,567
+7% +$53.7K ﹤0.01% 2415
2022
Q4 		$835K Buy
239,175
+1,869
+0.8% +$16.4K ﹤0.01% 2153
2022
Q3 		$8.79M Sell
237,306
-1,827
-0.8% -$50.6K 0.01% 1000
2022
Q2 		$4.54M Buy
239,133
+560
+0.2% +$12.2K ﹤0.01% 1336
2022
Q1 		$6.44M Buy
238,573
+228,414
+2,248% +$4.72M ﹤0.01% 1283
2021
Q4 		$229K Sell
10,159
-6,322
-38% -$141K ﹤0.01% 3315
2021
Q3 		$432K Buy
16,481
+820
+5% +$21.9K ﹤0.01% 3142
2021
Q2 		$501K Sell
15,661
-357
-2% -$12.4K ﹤0.01% 3221
2021
Q1 		$563K Buy
16,018
+4,411
+38% +$154K ﹤0.01% 3023
2020
Q4 		$371K Buy
11,607
+3,790
+48% +$130K ﹤0.01% 3108
2020
Q3 		$294K Buy
7,817
+681
+10% +$26.3K ﹤0.01% 2981
2020
Q2 		$320K Buy
+7,136
New +$302K ﹤0.01% 2874

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deutsche Bank's RLMD Position: Q2 2026 in Review

Deutsche Bank increased its Relmada Therapeutics (RLMD) stake by 42% in Q2 2026, buying an estimated $657K and bringing the position to 318,902 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1851.

Deutsche Bank first reported a position in RLMD in Q2 2020 and has held it in 25 quarters since. The position peaked at $8.79M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Deutsche Bank held 318,902 shares of Relmada Therapeutics worth $2.21M as of Q2 2026.
  • Deutsche Bank bought 94,056 Relmada Therapeutics shares in Q2 2026, an estimated $657K.
  • Relmada Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1851 holding.
  • Deutsche Bank first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Deutsche Bank's Relmada Therapeutics position peaked at $8.79M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.